REDWOOD CITY, Calif.--(BUSINESS WIRE)--Autonomic Technologies, Inc. (ATI), the developer of the Pulsante™ microstimulator for the treatment of severe headaches, is pleased to congratulate Dr. Frank Papay for being recognized as one of WebMD’s Health Heroes last week at an awards gala in New York City.
The event, which was hosted by Robin Roberts of Good Morning America, honors “top activists, researchers, and philanthropists who are changing the American health landscape.” Additional honorees were Michael J. Fox, Carson Daly, Dr. Harold S. Koplewicz, Zarin Ibnat Rahman and Martha Stewart.
“Dr. Papay conceived of the insertion procedure and location for the Pulsante microstimulator. It was a critical insight in the development of the product, which could one day transform the quality of life for millions of people suffering from severe headaches,” said Ben Pless, President and CEO of ATI. “We are very pleased that he has received this well-deserved recognition.”
The Pulsante microstimulator is currently being studied for the treatment of cluster headache in the U.S. (http://clinicaltrials.gov/ct2/show/NCT02168764). It is available commercially in Europe, as it already has CE mark. To date in Europe, Pulsante has been used successfully to treat thousands of cluster headache attacks.
Approximately 375,000 people in the U.S. suffer from cluster headaches, often called ‘suicide headache’. The pain caused by cluster attacks is one of the most severe pains known to humans. Many sufferers are unable to fully participate in life, work, or the activities they enjoy with family and friends. The socioeconomic burden of cluster headache on the individual and society is high due to costs of healthcare and costs of lost workdays and decreased work efficacy.
About Autonomic Technologies
Autonomic Technologies, Inc. (ATI) is a medical device company that develops and commercializes innovative therapies for the treatment of severe headache. The company’s initial product, the Pulsante™ SPG Microstimulator System (ATI Neurostimulation System), is CE marked in Europe for the treatment of cluster headache.
The ATI Neurostimulation System was voted #2 among the Cleveland Clinic’s top 10 medical innovations for 2013 and was chosen to receive a 2013 Best of What’s New Award from Popular Science in the Health category. ATI was named one of FierceMedicalDevices’ 2012 Fierce 15 most promising privately held medical device and diagnostics companies in the world.
ATI is headquartered in the San Francisco Bay Area and is backed by blue chip investors Kleiner Perkins Caufield and Byers, InterWest Partners, Versant Ventures, Novartis Ventures, Aberdare Ventures, and the Cleveland Clinic. For more information, visit www.ati-spg.com.
